Better Therapeutics- Tradeable Rights - March 2021 EBIT

Better Therapeutics- Tradeable Rights - March 2021's ebit stands at $-32M as of September 2023. That compares with $-42M in the prior-year period — up 24.1% year over year. That is above the sector sector average of $-69M. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Better Therapeutics- Tradeable Rights - March 2021 reported $-32M in EBIT versus $-42M a year earlier — a 24.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Better Therapeutics- Tradeable Rights - March 2021 sits higher the its sector benchmark ($-69M) with a EBIT of $-32M. That is roughly 53.7% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-42M in the prior-year period — up 24.1% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Better Therapeutics- Tradeable Rights - March 2021's EBIT evolved across reporting periods, while the comparison chart places MCADR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.